ArticleClinical rheumatology2021

Biologic disease-modifying anti-rheumatic drugs and kinase inhibitors: differences in efficacy and safety in rheumatoid arthritis.

Roy FleischmannPubMed ↗Publisher ↗

No numbers read from the abstract.